The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer
Research over the last decade has determined that the gene rearrangement involving the anaplastic lymphoma kinase (ALK) gene is an oncogenic driver in approximately 5% of patients with non-small cell lung carcinoma (NSCLC). This review describes the discovery of the ALK translocation, development of ALK directed therapy, and acquired resistance to ALK directed therapy with a focus on the clinical data and efficacy of the most recently approved ALK inhibitor, ceritinib.
Source: Therapeutic Advances in Respiratory Disease - Category: Respiratory Medicine Authors: Kaczmar, J., Mehra, R. Tags: Reviews Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Genetics | Lung Cancer | Lymphoma | Non-Small Cell Lung Cancer | Respiratory Medicine | Translocation